Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952650 | 0.90 | SMN1; SMN2 (0.51) | SMN1; SMN2POLBLMNAUSP2HPGD | |
| SCHEMBL9405372 | 0.88 | POLB (0.73) | SMN1; SMN2POLBLMNAHRH2HRH1 | |
| SCHEMBL22407745 | 0.85 | MEN1 (0.49) | SMN1; SMN2POLBLMNAUSP2HPGD | |
| SCHEMBL1189317 | 0.84 | ALDH1A1 (0.56) | SMN1; SMN2POLBLMNAUSP2HPGD | |
| SCHEMBL15932258 | 0.83 | POLB (0.59) | SMN1; SMN2POLBLMNAHRH2HRH1 | |
| SCHEMBL18760263 | 0.83 | HRH2 (0.51) | SMN1; SMN2POLBLMNAHRH2HRH1 | |
| SCHEMBL28898794 | 0.83 | USP2 (0.51) | SMN1; SMN2LMNAUSP2HPGDGPR119 | |
| SCHEMBL524083 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2POLBLMNAHRH2HRH1 | |
| SCHEMBL4321429 | 0.81 | USP2 (0.50) | SMN1; SMN2POLBLMNAUSP2HPGD | |
| SCHEMBL113667 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBLMNAUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-8466156-B2 | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| EP-2283011-B1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-23 | — | — | EP | disclosed |
| US-8058263-B2 | Substituted 2-phenyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-24 | — | — | US | disclosed |
| EP-2283011-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| EP-2279191-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-02 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009125366-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125365-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | SMN1; SMN2 4406/4885POLB 1874/4885LMNA 977/4885 |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | P2RY12, P2RY13, P2RY11 | SMN1; SMN2 3114/4885POLB 4086/4885LMNA 2647/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | SMN1; SMN2 4214/4885POLB 2236/4885LMNA 1671/4885 |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | P2RY12, P2RY13, P2RY4 | SMN1; SMN2 3027/4885POLB 3634/4885LMNA 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.